1 week Ago By ABMN Staff
Commonwealth Equity Services LLC cut its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 16.3% in the fourth quarter, according to its most recent disclosure with the SEC.
The firm owned 76,397 shares of the biotechnology company’s stock after selling 14,924 shares during the period. Commonwealth Equity Services LLC’s holdings in Pacific Biosciences of California were worth $140,000 at the end of the most recent quarter. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company.
Prosperity Wealth Management Inc. purchased a new stake in shares of Pacific Biosciences of California during the fourth quarter worth about $146,000. Wealthfront Advisers LLC boosted its holdings in Pacific Biosciences of California by 50.
8% in the 4th quarter. Wealthfront Advisers LLC now owns 62,648 shares of the biotechnology company’s stock worth $115,000 after buying an additional 21,092 shares during the last quarter. Vestmark Advisory Solutions Inc.
increased its stake in Pacific Biosciences of California by 44.5% during the 4th quarter. Vestmark Advisory Solutions Inc.
now owns 897,058 shares of the biotechnology company’s stock worth $1,642,000 after buying an additional 276,351 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Pacific Biosciences of California during the fourth quarter valued at approximately $253,000.
Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Pacific Biosciences of California by 6.7% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 2,176,252 shares of the biotechnology company’s stock valued at $3,983,000 after acquiring an additional 135,949 shares in the last quarter. Insider Transactions at Pacific Biosciences of California In other Pacific Biosciences of California news, insider Michele Farmer sold 24,349 shares of the company’s stock in a transaction dated Tuesday, February 18th.
The shares were sold at an average price of $1.88, for a total value of $45,776.12.
Following the transaction, the insider now owns 187,592 shares of the company’s stock, valued at $352,672.96. This represents a 11.
49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link . Company insiders own 2.
40% of the company’s stock. Wall Street Analyst Weigh In Check Out Our Latest Report on Pacific Biosciences of California Pacific Biosciences of California Stock Performance NASDAQ:PACB opened at $1.38 on Friday.
The company’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.72.
Pacific Biosciences of California, Inc. has a 1-year low of $1.08 and a 1-year high of $3.
47. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.
74 and a quick ratio of 8.64. The firm has a market capitalization of $411.
04 million, a price-to-earnings ratio of -0.84 and a beta of 2.04.
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) last released its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.
20). The firm had revenue of $39.22 million for the quarter, compared to analysts’ expectations of $39.
20 million. Pacific Biosciences of California had a negative return on equity of 42.89% and a negative net margin of 200.
40%. During the same period in the prior year, the firm posted ($0.27) earnings per share.
Analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current year.
About Pacific Biosciences of California ( Free Report ) Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. Read More Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ). Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.
com's FREE daily email newsletter ..
